Last reviewed · How we verify
JE-VAX® vaccine
JE-VAX® vaccine is a Biologic drug developed by Sanofi. It is currently in Phase 2 development. Also known as: JE-VAX®.
At a glance
| Generic name | JE-VAX® vaccine |
|---|---|
| Also known as | JE-VAX® |
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (PHASE1, PHASE2)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries (PHASE3)
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study (PHASE3)
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. (PHASE4)
- Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults (PHASE2)
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JE-VAX® vaccine CI brief — competitive landscape report
- JE-VAX® vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about JE-VAX® vaccine
What is JE-VAX® vaccine?
JE-VAX® vaccine is a Biologic drug developed by Sanofi.
Who makes JE-VAX® vaccine?
JE-VAX® vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is JE-VAX® vaccine also known as anything else?
JE-VAX® vaccine is also known as JE-VAX®.
What development phase is JE-VAX® vaccine in?
JE-VAX® vaccine is in Phase 2.
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: JE-VAX®
- Compare: JE-VAX® vaccine vs similar drugs
- Pricing: JE-VAX® vaccine cost, discount & access